[{"id":"57d644a2-7988-4d7c-b469-e62a58aafbfa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02960646","created_at":"2021-01-18T14:32:35.822Z","updated_at":"2024-07-02T16:35:55.351Z","phase":"Phase 1","brief_title":"Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies","source_id_and_acronym":"NCT02960646","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • DNMT3A • ASXL1 • KMT2A • TET2 • PHF6","pipe":" | ","alterations":" FLT3 mutation • DNMT3A mutation • Chr t(4;14) • Chr t(14;16) • MLL rearrangement","tags":["FLT3 • DNMT3A • ASXL1 • KMT2A • TET2 • PHF6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • DNMT3A mutation • Chr t(4;14) • Chr t(14;16) • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/18/2017","start_date":" 01/18/2017","primary_txt":" Primary completion: 02/13/2023","primary_completion_date":" 02/13/2023","study_txt":" Completion: 02/13/2023","study_completion_date":" 02/13/2023","last_update_posted":"2023-02-16"},{"id":"8685c132-e923-4108-8205-2e1925660d94","acronym":"PCR-LMA","url":"https://clinicaltrials.gov/study/NCT04446741","created_at":"2021-01-18T21:23:54.145Z","updated_at":"2024-07-02T16:36:24.804Z","phase":"","brief_title":"Molecular Diagnostic Platform for AML","source_id_and_acronym":"NCT04446741 - PCR-LMA","lead_sponsor":"PETHEMA Foundation","biomarkers":" TP53 • FLT3 • IDH2 • NPM1 • RUNX1 • WT1 • CEBPA • PHF6 • RAD21 • BRINP3 • SMC1A","pipe":" | ","alterations":" NPM1 mutation • U2AF1 mutation • CEBPA mutation","tags":["TP53 • FLT3 • IDH2 • NPM1 • RUNX1 • WT1 • CEBPA • PHF6 • RAD21 • BRINP3 • SMC1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • U2AF1 mutation • CEBPA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 10/01/2019","start_date":" 10/01/2019","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2021-09-06"}]